HNWAG
ONCY

High Net Worth Advisory Group’s Oncolytics Biotech ONCY Stock Holding History

High Net Worth Advisory Group’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-500
Closed -$1K – 707
2022
Q1 		$1K Buy
+500
New +$839 ﹤0.01% 665

Other funds holding ONCY

ARC
Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

High Net Worth Advisory Group's ONCY Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Oncolytics Biotech (ONCY) in Q2 2022, closing a stake of 500 shares — an estimated $1K sold.

High Net Worth Advisory Group first reported a position in ONCY in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 42 funds tracked by Wall St. Rank hold ONCY as of Q2 2022.

  • High Net Worth Advisory Group reported no remaining Oncolytics Biotech position as of Q2 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Oncolytics Biotech shares in Q2 2022, an estimated $1K.
  • High Net Worth Advisory Group first reported a position in Oncolytics Biotech in Q1 2022 and held it in 1 quarter.
  • High Net Worth Advisory Group's Oncolytics Biotech position peaked at $1K in Q1 2022.
  • 42 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.